Detalhe da pesquisa
1.
Phase Ib study of the mitochondrial inhibitor ME-344 plus topotecan in patients with previously treated, locally advanced or metastatic small cell lung, ovarian and cervical cancers.
Invest New Drugs
; 35(5): 627-633, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28283779
2.
CNS Downstaging: An Emerging Treatment Paradigm for Extensive Brain Metastases in Oncogene-Addicted Lung Cancer.
Lung Cancer
; 178: 103-107, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36809719
3.
Short communication: The activity of brigatinib in patients with disease progression after next generation anaplastic lymphoma tyrosine kinase inhibitors and an exploratory analysis of circulating tumor DNA.
Lung Cancer
; 165: 43-48, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-35085983
4.
Veliparib and nivolumab in combination with platinum doublet chemotherapy in patients with metastatic or advanced non-small cell lung cancer: A phase 1 dose escalation study.
Lung Cancer
; 161: 180-188, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34607210
5.
Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer.
Lung Cancer
; 144: 10-19, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32344248
6.
Detection of oligoprogressive disease in oncogene-addicted non-small cell lung cancer using PET/CT versus CT in patients receiving a tyrosine kinase inhibitor.
Lung Cancer
; 126: 112-118, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30527174
7.
Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer.
ESMO Open
; 2(3): e000219, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-29209525
8.
Corrigendum: Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.
Nat Commun
; 7: 13513, 2016 11 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-27841271